primary endpoint

Type: Keyphrase

Name: primary endpoint

First reported May 24 2013 - Updated May 24 2013 - 1 reports

Repros Needs Another Mid-Stage Trial For Proellex In Uterine Fibroids

FDA also recommends longer-duration Phase III trials of the vaginally-administered selective progesterone receptor modulator than the sponsor envisioned. Primary endpoint will measure blood loss; agency stresses that bulk symptoms and other patient-reported ... [Published The Rose Sheet - May 24 2013]

Entities: Progesterone, primary endpoint, Receptor

First reported May 23 2013 - Updated May 23 2013 - 1 reports

AstraZeneca PLC

Data on AstraZeneca's Naloxegol

AstraZeneca (AZN) recently presented data on naloxegol (25 mg once daily) from two pivotal phase III studies (KODIAC-04 and -05) at the Digestive Disease Week (:DDW) meeting. Top-line results from this study were initially presented in Nov 2012.Naloxegol, ... [Published Yahoo! Finance - May 23 2013]

Entities: naloxegol, AstraZeneca PLC, primary endpoint, Phase III

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Comparative effectiveness of a complex Ayurvedic treatment and conventional standard care in ...

Traditional Indian Ayurvedic medicine uses complex treatment approaches, including manual therapies, lifestyle and nutritional advice, dietary supplements, medication, yoga, and purification techniques. Ayurvedic strategies are often used to treat osteoarthritis ... [Published 7thSpace - May 23 2013]

Entities: Osteoarthritis, Patient, Index, American College of Rheumatology

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Oncolytics Biotech Q1 net loss decreases

Oncolytics Biotech Inc., a biotechnology company, has reported that net loss for the first quarter ended March 31, 2013 was C$6.61 million, or $0.08 loss per share, compared to a net loss of C$8.46 million, or $0.11 loss per share, for the same quarter ... [Published Individual.com - May 23 2013]

Entities: Oncolytics Biotech Inc, Brad Thompson, squamous cell carcinoma, primary endpoint

First reported May 22 2013 - Updated May 23 2013 - 2 reports

REPRISE II trial: Lotus Valve System meets primary endpoint in severe aortic valve disease patients

Boston Scientific Corporation (NYSE: BSX) reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II trial evaluating the performance and safety of the Lotus™ Valve System in symptomatic patients with severe ... [Published News-Medical.Net - May 23 2013]

Entities: Aortic Valve, Patient, primary endpoint

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Sanofi SA

Sanofi Highlights Positive PhIII Study for Myelofibrosis Contender

Fierce Biotech (05/17/13) McBride, Ryanbody: Sanofi has released some of the results from its phase III trial of SAR302503, a JAK2 inhibitor used to treat myelofibrosis. The study met its primary endpoint for the proportion of patients who experienced ... [Published AAPS Pharmceutica - May 23 2013]

Entities: myelofibrosis, Sanofi SA, Jakafi, Incyte Corporation

First reported May 22 2013 - Updated May 22 2013 - 5 reports

Phase II

Oncolytics Biotech Inc Meets Primary Endpoint For First Stage Of U.S. Phase 2 Metastatic Melanoma Trial

Oncolytics Biotech Inc announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastatic melanoma using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 020). The Principal Investigator ... [Published Reuters - May 22 2013]

Entities: Metastatic, Oncolytics Biotech Inc, Skin Cancer, Phase II, primary endpoint

First reported May 21 2013 - Updated May 21 2013 - 2 reports

AcelRx: Primary Endpoint Met In Late-stage Study Of NanoTab System

AcelRx Pharmaceuticals, Inc.(ACRX: Quote), Tuesday said a late-stage study of its investigational sublingual Sufentanil NanoTab PCA System (NanoTab System) reached primary endpoint. Results showed that patients receiving Sufentanil NanoTab after major ... [Published RTTNews.com - May 21 2013]

Entities: AcelRx Pharmaceuticals Inc, primary endpoint, Sufentanil, Richard King, Orthopedic Surgery

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Advanced Cell Technology (ACTC.OB) Better vision after treatments

Clinical trial participant showed vision improvement from 20/400 to 20/40The vision of a patient enrolled in a clinical investigation of the retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) has improved from 20/400 ... [Published Proactive Investors USA - May 21 2013]

Entities: Advanced Cell Technology Inc, treatments, epithelial, Embryonic Stem Cell

First reported May 21 2013 - Updated May 21 2013 - 1 reports

BioMarin Pharmaceutical Inc. Presents at UBS Global Healthcare Conference, May-21-2013 09:00 AM

Matthew Harrison - UBS Investment Bank, Research DivisionGood morning, everybody. Thanks for joining us. I'm Matthew Harrison, one of the Biotech analyst here at UBS. Next up, we have BioMarin and I'm pleased to have the CFO, Dan Spiegelman presenting. ... [Published Seeking Alpha - May 21 2013]

Entities: Patient, BioMarin Pharmaceutical Inc, Phase III, FDA Food & Drug Administration

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Home Deport gains on strong results

Earnings, Sales Beat ExpectationsHome Depot earned $0.83 a share in the first quarter, better than the $0.77 expected by analysts. Sales of $19.12 billon also beat the $18.68 billion consensus estimate, and management raised full-year guidance thanks ... [Published Yahoo! Finance - May 21 2013]

Entities: AcelRx Pharmaceuticals Inc, Phase III, Cameroon

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Amgen's Phase III colorectal cancer trial meets primary endpoint

Amgen Inc., a biotechnology company, has announced that the Phase III head-to-head ASPECCT trial evaluating Vectibix versus Erbitux as a single agent for the treatment of chemorefractory metastatic colorectal cancer, or mCRC, in patients with wild-type ... [Published Individual.com - May 20 2013]

Entities: Vectibix, Erbitux, primary endpoint, Phase III, Colorectal Cancer

Quotes

"Mortality in diabetes: pancreas transplantation is associated with significant survival benefit." Nephrology Dialysis Transplantation. (2013) 28 (5): 1315-1322. doi: 10.1093/ndt/gfs613

Pancreas Transplant Significantly Reduces Mortality in Type 1 Diabetes Patients [Published Diabetes in Control - May 24 2013]

...The title of Dr Bartus' talk was: "CERE-120 (AAV2- neurturin) for the treatment of Parkinson's disease: Experience from 4 clinical trials and human autopsy data"

Ceregene announces additional efficacy data from phase IIb study of CERE-120 to treat Parkinson's ... [Published PharmaBiz - May 24 2013]

..." He added, "As the number of patients in this highly interesting multicentre trial was relatively small (200 patients), a large-scale randomised controlled trial including a health economic assessment of both diagnostic options for routine use is justified."

Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases [Published Medical Xpress - May 24 2013]

...He added, "Successful delivery and deployment of the HELIO System and retrieval of the delivery systems resulting in improved aortic insufficiency in the earliest evaluable echocardiogram post-implant was achieved in all four patients." Aortic insufficiency improved from moderate to severe before the procedure to trivial at 30 days...

Feasibility trial reports deployment of new device for TAVI in aortic insufficiency [Published Medical Xpress - May 24 2013]

More Content

sort by: Date \| Relevance
Pfizer’s Setback and 5 Top Stories Affecting Do... [Published Wall St. Cheat Sheet - 6 hours ago]
Pfizer’s Setback and 5 Top Stories Affecting Do... [Published Wall St. Cheat Sheet - 6 hours ago]
Lilly Treatment Slows Alzheimer’s Course in Som... [Published Bloomberg - 12 hours ago]
InspireMD's MGuard Embolic Protection Stent Sho... [Published Diagnostic & Invasive Cardiology - May 24 2013]
Promising Data on ONCY's Reolysin Zacks [Published Yahoo! Finance - May 24 2013]
Pancreas Transplant Significantly Reduces Morta... [Published Diabetes in Control - May 24 2013]
Pfizer Discontinues Its Inotuzumab Evaluation a... [Published Wall St. Cheat Sheet - May 24 2013]
Repros Needs Another Mid-Stage Trial For Proell... [Published The Rose Sheet - May 24 2013]
Pfizer Discontinues Its Inotuzumab Evaluation a... [Published Wall St. Cheat Sheet - May 24 2013]
Acadia: Multiple Data Points Suggest Further Up... [Published Seeking Alpha - May 24 2013]
Ceregene announces additional efficacy data fro... [Published PharmaBiz - May 24 2013]
Diagnostic coronary angiography: Functional flo... [Published Medical Xpress - May 24 2013]
Feasibility trial reports deployment of new dev... [Published Medical Xpress - May 24 2013]
A Review Of Upcoming Catalysts For Kidney Disea... [Published Seeking Alpha - May 24 2013]
Direct Flow Medical's Transcatheter Aortic Valv... [Published Medical Devices Business Review - May 24 2013]
Prosonix begins phase II study with PSX1002 in ... [Published PharmaBiz - May 24 2013]
Biotech Stock Mailbag: Amarin, MannKind, Palatin [Published TheStreet.com - May 24 2013]
Hepatic Encephalopathy: Probiotics found to red... [Published NewsRX - May 24 2013]
Covidien announces results from SURF trial usin... [Published Medical Devices Business Review - May 24 2013]
Study Seeks to Eliminate Clinical Barriers to B... [Published OncLive - May 24 2013]
[Articles] Selective oestrogen receptor modulat... [Published Lancet - May 24 2013]
[Correspondence] Not time to RELAX in acute hea... [Published Lancet - May 24 2013]
New Drug May Change Treatment Of Asthma [Published Forbes.com - May 24 2013]
EuroPCR 2013: Medtronic, St. Jude to build case... [Published Medical Device Daily - May 24 2013]
Boston Scientific Schedule of Major Events and ... [Published NewsRX - May 24 2013]
Stentys Cardiac Stent Reduces Heart Attack Rate... [Published QMED - May 24 2013]
Encouraging News for Peregrine Pharma - Analyst... [Published Quote.com Australia - May 24 2013]
Data on AstraZeneca's Naloxegol [Published Yahoo! Finance - May 23 2013]
Repros to Conduct Phase IIb Trial Zacks [Published Yahoo! Finance - May 23 2013]
Biogen Submits Plegridy BLA [Published Yahoo! Finance - May 23 2013]